Novo Nordisk’s Wegovy Broadens Its Reach: UK MASH Nod, Medicare Push, and a Billion-Dollar Parent Exit
Published on 07/06/2026 at 11:42 | Redaktion boerse-global.de
Novo Nordisk’s bestselling GLP-1 drug is no longer tethered solely to obesity. The Danish pharma giant has locked in a new UK approval for Wegovy against the metabolic liver condition MASH, while a freshly launched Medicare program in the US is putting the shot within reach of millions of older Americans. Away from the operating table, the company’s controlling shareholder just cashed out on a biotech bet worth up to $1.5 billion.
Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) formally cleared Wegovy for moderate-to-severe liver fibrosis tied to metabolic dysfunction-associated steatohepatitis on 3 July 2026. The decision adds a third indication to the drug’s label in the UK, following obesity and cardiovascular risk. The US Food and Drug Administration had already given its blessing for MASH patients, though advanced cirrhosis cases remain excluded.
On the other side of the Atlantic, the Medicare Bridge Program kicked off at the start of July, slashing Wegovy’s monthly cost to roughly $50 for eligible beneficiaries. The government-backed initiative runs through the end of 2027, and analysts expect a significant uptake in prescriptions over the coming months. Eli Lilly is operating under identical pricing terms, so Novo Nordisk cannot lean on a cost advantage to pull ahead of its chief rival.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The parent company Novo Holdings, meanwhile, has orchestrated a tidy exit from its investment in Myricx Bio. The research-stage startup, which Novo Holdings helped finance, is being acquired by Novartis. The deal carries a total value of up to $1.5 billion, with $1.1 billion due as an upfront cash payment. The move underscores the parent’s strategy of backing promising platforms and monetising them when the time is right.
Investors have rewarded the flurry of positive news. The stock has climbed roughly 17% over the past 30 days, trading at €43.74 in Copenhagen, and has advanced nearly 20% in the last few weeks alone, breaking decisively above the 200-day moving average. Yet the longer-term picture remains sobering: the shares are still down around 26% year to date. The relative strength index now sits at 72, suggesting the recent rally has pushed the equity into moderately overbought territory.
The next big dates are 5 August, when Novo Nordisk reports second-quarter results, and 21 September, when management will lay out fresh financial targets at its Capital Markets Day. By expanding Wegovy into metabolic liver disease and widening access through Medicare, the company is chipping away at its dependence on pure weight loss revenue — a strategy that becomes more critical as competition in the GLP-1 space intensifies.
Ad
Novo Nordisk Stock: New Analysis - 6 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
